doi: 10.3389/fimmu.2018.02061 162 LevringT
A shot typically causes little to no pain
While further clinical validation is needed, science has mapped its molecular blueprintushering in a new era of combating aging and disease with this cellular battery booster. References 1.Chowanadisai, W., et al
What alternatives exist if I don't want continuous GLP-1
The guidelines state, GLP-1 RAs may be considered for weight-loss in patients who have completed cancer therapy and may be considered with caution for patients on stable endocrine-based cancer therapies based on limited observational safety data. They also say, GLP-1 RAs cannot be recommended currently for patients receiving or initiating chemotherapies and/or immunotherapies due to lack of safety and outcomes data. Iyengar is director of Survivorship Services at Winship Cancer Institute of Emory University, a clinical member of Winships Glenn Family Breast Center, an associate professor and co-director of the Breast Medical Oncology Program in the Department of Hematology and Medical Oncology at Emory University School of Medicine, and co-editor-in-chief of the journal ONCOLOGY
When NNMT activity is high: NAD levels drop, impairing mitochondrial energy production